Florida 2024 2024 Regular Session

Florida Senate Bill S0056 Analysis / Analysis

Filed 01/23/2024

                    The Florida Senate 
BILL ANALYSIS AND FISCAL IMPACT STATEMENT 
(This document is based on the provisions contained in the legislation as of the latest date listed below.) 
Prepared By: The Professional Staff of the Committee on Banking and Insurance  
 
BILL: CS/SB 56 
INTRODUCER:  Senate Committee on Banking and Insurance and Senator Harrell 
SUBJECT:  Coverage for Skin Cancer Screenings 
DATE: January 23, 2024 
 
 ANALYST STAFF DIRECTOR  REFERENCE  	ACTION 
1. Thomas Knudson BI Fav/CS 
2.     HP  
3.     AP  
 
Please see Section IX. for Additional Information: 
COMMITTEE SUBSTITUTE - Substantial Changes 
 
I. Summary: 
CS/SB 56 requires all contracted state group health insurance plans and HMO’s to cover and pay 
for annual skin cancer screenings performed by a Florida licensed dermatologist. The bill 
prohibits an insurer or HMO from imposing any cost-sharing requirement for the annual skin 
cancer screening, including a deductible, copayment, coinsurance, or any other type of cost-
sharing. The provider conducting the screening must be a dermatologist licensed as a medical 
doctor under chapter 458, F.S., or an osteopathic physician licensed under chapter 459, F.S, or an 
advanced practice registered nurse licensed under chapter 464 who is under the supervision of a 
dermatologist licensed under chapter 458 or chapter 459. 
 
The bill requires payment for such annual skin cancer screenings to be consistent with the 
insurer’s or HMO’s payments for other preventive screenings. Additionally, the bill prohibits the 
insurer or HMO from bundling a payment for a skin cancer screening with any other procedure 
or service, including an evaluation or management visit, which is performed during the same 
office visit or subsequent office visit. 
 
The Division of State Group Insurance within the Department of Management Services (DMS) 
estimates that the bill will result in an annual increase of $357,580 on the state employee group 
health plan.  
 
The bill provides an effective date of July 1, 2024. 
REVISED:   BILL: CS/SB 56   	Page 2 
 
II. Present Situation: 
Background  
Skin cancer is the most common cancer in the United States.
1
 Approximately one in five 
Americans will develop skin cancer in their lifetime.
2
 It is estimated that approximately 9,500 
people in the U.S. are diagnosed with skin cancer every day.
3
 Nearly 20 Americans die from 
melanoma every day.
4
 Cancer is the second most common cause of death in the United States 
after heart disease and in 2023, a total of 1.9 million new cancer cases were diagnosed. Of the 
estimated new cancer cases in the United States, 5 percent were skin cancer cases.
5
 
 
Basal cell and squamous cell cancers are called nonmelanoma skin cancer, and are the most 
common of skin cancers. Melanoma accounts for about 1 percent of skin cancers but causes a 
large majority of skin cancer deaths.
6
 The long term survival rate of those diagnosed with skin 
cancer after 5 years is high at 93.5 percent and more than 1.4 million people were identified in 
the United States in 2020 as living with this cancer.
7
 The more localized the cancer is when it is 
found, meaning the cancer has been confined to a primary spot, the higher the survival rate is 
compared to a cancer that has spread to the regional lymph nodes or metastasized to another 
region of the body.
8
  
 
For Florida, the estimated new cases of melanoma skin cancer for 2023 is 9,640 with projected 
deaths of 680 individuals.
9
 Of the top five cities in the U.S. for skin cancer prevalence rate, four 
are in Florida – Sarasota-Bradenton (10 percent), Fort Pierce-Port St. Lucie (9.5 percent), West 
Palm Beach-Boca Raton (9.5 percent), and Melbourne-Titusville-Palm Bay (8.6 percent).
10
  
 
Skin Cancer Screening  
During a skin cancer screening test, a doctor or nurse checks a patient’s skin for moles, 
birthmarks, or other pigmented areas that may be abnormal in color, size, shape, or texture. If an 
area looks abnormal, a biopsy of the area may be done where the health care provider may 
                                                
1
 Guy GP, Thomas CC, et al., Vital signs: Melanoma incidence and mortality trends and projections – United States, 1982-
2030, MMWR Morb Mortal Wkly Rep. 2015;64(21):591-596. 
2
 Sterns RS, Prevalence of a history of skin cancer in 2007: results of an incidence-based model, Arch Dermatol. 2010 
Mar.;146(3):279-282. 
3
 Rogers HW, Weinstock MA, et al., Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US 
population, JAMA Dermatol, April 30, 2015, available at https://pubmed.ncbi.nlm.nih.gov/25928283/ (last viewed on 
January 18, 2024). 
4
 https://www.cancercenter.com/community/blog (last viewed January 18, 2024).  
5
 Id. 
6
 American Cancer Society, Key Statistics for Melanoma Skin Cancer, available at https://www.cancer.org/melanoma-skin-
cancer/about/key-statistics.html (last viewed on January 18, 2024). 
7
 National Cancer Institute, Cancer Stat Facts: Melanoma of the Skin, available at 
https://seer.cancer.gov/statfacts/html/melan.html (last viewed January 18, 2024). 
8
 National Cancer Institute, Cancer Stat Facts: Melanoma of the Skin, Survival by State, available at 
https://seer.cancer.gov/statfacts/html/melan.html (last viewed January 18, 2024). 
9
 American Cancer Society, Cancer Statistics Center, Estimated New Cancer Cases and Deaths by States (sexes combined, 
Florida) (data run on January 18, 2024) available at Cancer Statistics Center - American Cancer Society (last viewed January 18, 2024). 
10
 Id.  BILL: CS/SB 56   	Page 3 
 
remove as much of the suspicious tissue as possible with a local excision. A pathologist reviews 
this tissue under a microscope to check for cancer cells.
11
  
 
In Illinois, where preventative skin cancer screenings are covered by health insurance companies, 
a large dermatology practice reports a 99.15% (stage 0-2) early melanoma detection rate 
compared to the industry average early melanoma detection rate of 83.00%.
12
 This results in a 
97.9% five-year melanoma survival rate compared to industry average 87.0% five-year 
melanoma survival rate.
13
 
 
Regulation of Insurance in Florida  
The Office of Insurance Regulation (OIR) regulates specified insurance products, insurers and 
other risk bearing entities in Florida.
14
 As part of their regulatory oversight, the OIR may 
suspend or revoke an insurer’s certificate of authority under certain conditions.
15
 The OIR is 
responsible for examining the affairs, transactions, accounts, records, and assets of each insurer 
that holds a certificate of authority to transact insurance business in Florida.
16
 As part of the 
examination process, all persons being examined must make available to the OIR the accounts, 
records, documents, files, information, assets, and matters in their possession or control that 
relate to the subject of the examination.
17
 The OIR is also authorized to conduct market conduct 
examinations to determine compliance with applicable provisions of the Insurance Code.
18
  
 
The Agency for Health Care Administration (AHCA) regulates the quality of care by HMOs 
under part III of ch. 641, F.S. Before receiving a certificate of authority from the OIR, an HMO 
must receive a Health Care Provider Certificate from AHCA.
19
 As part of the certificate process 
used by the agency, an HMO must provide information to demonstrate that the HMO has the 
ability to provide quality of care consistent with the prevailing standards of care.
20
 
 
                                                
11
 National Cancer Institute, Skin Cancer Screening (PDQ) – Patient Version, available at Skin Cancer Screening - NCI (last 
viewed January 18, 2024). 
12
 Almutairi, et al. Economic Evaluation Patients with Advanced Unresectable Melanoma versus Economic valuation of 
Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced 
Unresectable Melanoma. JAMA Dermatology. January 2019; 155(1):22-28. 
13
 Id. 
14
 Section 20.121(3)(a), F.S. The Financial Services Commission, composed of the Governor, the Attorney General, the Chief 
Financial Officer, and the Commissioner of Agriculture, serves as agency head of the Office of Insurance Regulation for 
purposes of rulemaking. Further, the Financial Services Commission appoints the commissioner of the Office of Insurance 
Regulation. 
15
 Section 624.418, F.S. 
16
 Section 624.316(1)(a), F.S. 
17
 Section 624.318(2), F.S. 
18
 Section 624.3161, F.S. 
19
 Section 641.21(1)(1), F.S. 
20
 Section 641.495, F.S.  BILL: CS/SB 56   	Page 4 
 
Patient Protection and Affordable Care Act  
Essential Benefits  
Under the Patient Protection and Affordable Care Act (PPACA),
21
 all non-grandfathered health 
plans in the non-group and small-group private health insurance markets must offer a core 
package of health care services known as the essential health benefits (EHBs). While not 
specifying the benefits within the EHB, the PPACA provides 10 categories of benefits and 
services which must be covered and then required the Secretary of Health and Human Services 
to further define the EHB.
22
  
 
The 10 EHB categories are: 
 Ambulatory patient services. 
 Emergency services. 
 Hospitalization. 
 Maternity and newborn care 
 Mental health and substance use disorder services, including behavioral health 
treatment. 
 Prescription drugs. 
 Rehabilitation and habilitation services. 
 Laboratory services. 
 Preventive and wellness services and chronic disease management. 
 Pediatric services, including oral and vision care. 
 
PPACA requires each state to select its own reference benchmark plan as its EHB benchmark 
plan which all other health plans in the state use as a model. Beginning in 2020, states could 
choose a new EHB plan using one of three options, including: selecting another’s state 
benchmark plan; replacing one or more categories of EHB benefits; or selecting a set of benefits 
that would become the State’s EHB benchmark plan.
23
 Florida selected its EHB plan before 2012 
and has not modified that selection.
24
  
 
State Insurance Coverage Mandates  
If a state elects to amend its benchmark plan later by imposing a statutory mandate to cover a 
new service, PPACA requires the state to pay for the additional costs of that mandate for the 
entire industry.
25
 According to a recent study, only two states have chosen to enhance their EHB 
                                                
21
 Affordable Care Act, (March 23, 2010), P.L.111-141, as amended. 
22
 45 CFR 156.100. et seq. 
23
 Centers for Medicare and Medicare Services, Marketplace – Essential Health Benefits, available at 
https://www.cms.gov/marketplace/resources/data/essential-health-benefits (last reviewed January 18, 2024). 
24
 Centers for Medicare and Medicaid Services, Information on Essential Health Benefits (EHB) Benchmark Plans, Florida 
State Required Benefits, available at https://downloads.cms.gov/cciio/State%20Required%20Benefits_FL.pdf (last viewed on 
January 18, 2024). 
25
 42 U.S.C. section 1803 U.S. Preventive Services Task Force, Skin Cancer Prevention: Behavioral Counseling (March 20, 
2018) available at Recommendation: Skin Cancer Prevention: Behavioral Counseling | United States Preventive Services 
Taskforce (uspreventiveservicestaskforce.org) (last reviewed January 18, 2024).  BILL: CS/SB 56   	Page 5 
 
benchmark plans and have incurred the additional benefits penalty: Utah and Massachusetts.
26
 
Utah, for example, added a coverage mandate for applied behavioral analysis therapy for 
individuals with autism in 2014 and subsequently implemented a state rule to allow the state to 
reimburse the estimated five affected carriers for the autism claims with state funds.
27
 
 
Annually, the federal Centers for Medicare and Medicaid Services issues a Notice of Benefit and 
Payment Parameters (NBPP) for the next plan year. The NBPP typically includes minor updates 
to coverage standards, clarifications to prior policy statements, and announcements relating to 
any major process changes. For the 2025 Plan Year which begins on January 1, 2025, the NBPP 
proposes to codify that any new, additional benefits included in a state’s EHB plan would not be 
considered an addition to the state’s EHB, and therefore not subject to the PPACA provision 
requiring the state to defray the cost for the industry.
28
 This change is part of a proposed rule 
which has not yet been finalized, so it is unclear whether the PPACA state defrayal provision 
will apply in future.
29
 
 
State Employee Health Plan  
For state employees who participate in the state employee benefit program, the Department of 
Management Services (DMS) through the Division of State Group Insurance (DSGI) administers 
the state group health insurance program (Program).
30
 The Program is a cafeteria plan managed 
consistent with section 125 of the Internal Revenue Service Code.
31
 To administer the program, 
DSGI contracts with third party administrators for self-insured plans, a fully insured HMO, and a 
pharmacy benefits manager for the state employees’ self-insured prescription drug program, 
pursuant to s.110.12315, F.S.  
 
The state employee health plan contracts currently cover dermatology visits and skin cancer 
screenings as a specialist office visit. Depending on the plan chosen by the employee, the 
appropriate out of pocket cost or costs then applies for the specialist office visit.
32
 
 
                                                
26
 California Health Benefits Program, (CHBRP) (August 2023), Issue Brief: Essential Health Benefits: Exceeding EHBs and 
the Defrayal Requirement, p.2. available at https://www.chbrp.org/sites/default/files/2023-08/EHB_Defrayal_FINAL.pdf 
(last viewed January 18, 2024). 
27
 Utah Admin. Code R590-283 – Notice of Proposed Rule (November 1, 2019), available at DAR File No. 44181 (Rule 
R590-283), 2019-22 Utah Bull. (11/15/2019)DAR File No. 44181 (Rule R590-283), 2019-22 Utah Bull. (11/15/2019) (last 
viewed January 18, 2024). 
28
 CMS.GOV, HHS Notice of Benefit and Payment Parameters for 2025 Proposed Rule (November 15, 2023), available at 
https://www.cms.gov/newsroom/fact-sheets/hhs-notice-benefit-and-payment-parameters-2025-proposed-rule (last viewed 
January 18, 2024). 
29
 Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2025; Updating Section 
1332 Waiver Public Notice Procedures; Medicaid; Consumer Operated and Oriented Plan (CO-OP) Program, and Basic 
Health Program, 88 Fed. Reg. 82510, 82553, 82630-82631, 82649, 82653-82654 (November 24, 2023)(to be codified at 
section 45 CFR 155.170 and 156.11). 
30
 Section 110.123, F.S. 
31
 A section 125 cafeteria plan is a type of employer offered, flexible health insurance plan that provides employees a menu 
of pre-tax and taxable qualified benefits to choose from, but employees must be offered at least one taxable benefit such as 
cash, and one qualified benefit, such as a Health Savings Account. 
32
 Department of Management Services, Agency Bill Analysis – HB 241/SB 56 (January 12, 2024) (on file with the Senate 
Committee on Banking and Insurance).  BILL: CS/SB 56   	Page 6 
 
Legislative Proposals for Mandated Health Benefit Coverage  
Any person or organization proposing legislation which would mandate health coverage or the 
offering of health coverage by an insurance carrier, health care service contractor, or health 
maintenance organization (HMO) as a component of individual or group policies, must submit to 
AHCA and the legislative committees having jurisdiction a report which assesses the social and 
financial impacts of the proposed coverage.33 Guidelines for assessing the impact of a proposed 
mandated or mandatorily offered health coverage, to the extent that information is available, 
must include: 
 To what extent is the treatment or service generally used by a significant portion of the 
population. 
 To what extent is the insurance coverage generally available. 
 If the insurance coverage is not generally available, to what extent does the lack of coverage 
result in persons avoiding necessary health care treatment. 
 If the coverage is not generally available, to what extent does the lack of coverage result in 
unreasonable financial hardship. 
 The level of public demand for the treatment or service. 
 The level of public demand for insurance coverage of the treatment or service. 
 The level of interest of collective bargaining agents in negotiating for the inclusion of this 
coverage in group contracts. 
 To what extent will the coverage increase or decrease the cost of the treatment or service. 
 To what extent will the coverage increase the appropriate uses of the treatment or service. 
 To what extent will the mandated treatment or service be a substitute for a more expensive 
treatment or service. 
 To what extent will the coverage increase or decrease the administrative expenses of 
insurance companies and the premium and administrative expenses of policyholders. 
 The impact of this coverage on the total cost of health care.
34
 
 
Proponents of the bill submitted a report to the Senate Committee on Banking and Insurance on 
March 7, 2023, to comply with s. 624.215, F.S., addressing the guidelines for assessing the 
impact of the proposed annual skin cancer screening mandated benefit, at no cost to the 
insured.
35
 
III. Effect of Proposed Changes: 
The bill requires all contracted state group health insurance plans and HMO’s to cover and pay 
for annual skin cancer screenings performed by a Florida licensed dermatologist. The bill 
prohibits an insurer or HMO from imposing any cost-sharing requirement for the annual skin 
cancer screening, including a deductible, copayment, coinsurance, or any other type of cost-
sharing. The provider conducting the screening must be a dermatologist licensed as a medical 
doctor under chapter 458, F.S., or an osteopathic physician licensed under chapter 459, F.S, or an 
                                                
33
 Section 624.215(2), F.S. 
34
 Section 624.215(2)(a)-(l), F.S. 
35
 Florida Academy of Dermatology, Coverage for Skin Cancer Screenings, March 2023 (Report submitted pursuant to s. 
624.215, F.S.) (on file with the Senate Committee on Banking and Insurance).  BILL: CS/SB 56   	Page 7 
 
advanced practice registered nurse licensed under chapter 464 who is under the supervision of a 
dermatologist licensed under chapter 458 or chapter 459, F.S. 
 
The bill requires payment for such annual skin cancer screenings to be consistent with the 
insurer’s or HMO’s payments for other preventive screenings as defined by the Current 
Procedural Terminology code set of the American Medical Association. Lastly, the bill prohibits 
such insurers and HMOs from bundling a payment for skin cancer screenings with any other 
procedure or service performed during the same or a subsequent office visit as the screening. 
 
The bill provides an effective date of July 1, 2024. 
IV. Constitutional Issues: 
A. Municipality/County Mandates Restrictions: 
None. 
B. Public Records/Open Meetings Issues: 
None. 
C. Trust Funds Restrictions: 
None. 
D. State Tax or Fee Increases: 
None. 
E. Other Constitutional Issues: 
None. 
V. Fiscal Impact Statement: 
A. Tax/Fee Issues: 
None. 
B. Private Sector Impact: 
The inclusion of coverage for skin cancer screenings with cost sharing restrictions may 
positively impact physicians who likely will see an increased demand for their services as 
well as collateral and ancillary medical supports such as laboratories and diagnostic 
offices which will be called upon to process additional lab slips, biopsies, and scans. 
 
The intent of the bill is to save costs, as well as lives, by detecting and treating skin 
cancers earlier.   BILL: CS/SB 56   	Page 8 
 
C. Government Sector Impact: 
The Division of State Group Insurance within the Department of Management Services 
(DMS) administers the State Group Insurance Program (SGI Program). For the state 
employee group health plan, the DMS has estimated an annual increase of $357,580 for 
no cost sharing liability in the coverage of annual skin cancer screenings. 
VI. Technical Deficiencies: 
None. 
VII. Related Issues: 
None. 
VIII. Statutes Affected: 
This bill substantially amends the following section of the Florida Statutes: 110.12303.  
IX. Additional Information: 
A. Committee Substitute – Statement of Substantial Changes: 
(Summarizing differences between the Committee Substitute and the prior version of the bill.) 
CS by Banking and Insurance Committee on January 22, 2024: 
The committee substitute removes the entire substance of the bill and amends s. 
110.12303, F.S., to provide that the provisions of the bill as filed apply only to the 
contracted state group health insurance plans and HMOs. 
B. Amendments: 
None. 
This Senate Bill Analysis does not reflect the intent or official position of the bill’s introducer or the Florida Senate.